SequelSEC

PROVECTUS BIOPHARMACEUTICALS, INC. PVCT

Pharmaceutical Preparations · CIK 0000315545 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$336.11K
Fiscal year ended 2025-12-31
Operating income
-$5.29M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported revenue of $336.11K and net income of -$5.43M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from PROVECTUS BIOPHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PROVECTUS BIOPHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312015-12-312014-12-31
Revenue$336.11K$617.14K$557.71K$989.04K$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$5.29M-$4.53M-$2.90M-$3.43M-$24.65M-$12.63M
Net income-$5.43M-$4.73M-$3.10M-$3.55M-$24.50M-$10.24M
Research & development$1.90M$2.05M$1.75M$2.39M$11.38M$5.81M
Weighted-average diluted sharesshares 420.28Mshares 419.81Mshares 419.51Mshares 419.47MUnavailableUnavailable
Pretax income-$5.51M-$4.77M-$3.10M-$3.55MUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable$0$0
Diluted EPS$-0.01$-0.01$-0.01$-0.01UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$3.73M$3.10M$1.71M$2.03M$13.27M$11.00M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PROVECTUS BIOPHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312015-12-312014-12-31
Cash & equivalents$251.29K$307.44K$76.58K$21.60K$14.18M$17.39M
Total assets$697.50K$1.01M$1.45M$2.04M$20.44M$26.18M
Current assets$567.87K$976.77K$1.36M$1.90M$14.72M$19.10M
Total liabilities$7.00M$6.98M$9.04M$8.27M$4.12M$994.28K
Current liabilities$6.90M$6.98M$9.02M$8.19M$4.12M$847.72K
Total equity incl. NCI-$6.30M-$5.97M-$7.59M-$6.23M$16.32M$25.19M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailable$476$394UnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$716.22K$1.11M$1.68M$2.09MUnavailableUnavailable

Cash flow

PROVECTUS BIOPHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312015-12-312014-12-31
Operating cash flow-$3.33M-$3.28M-$2.57M-$3.04MUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailable$6.14K$70.59K
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailable-$70.59K
Financing cash flow$3.09M$2.75M$2.19M$1.37MUnavailableUnavailable
Net change in cash-$238.44K-$537.07K-$404.91K-$1.68M-$3.21M$1.70M
Stock-based compensation$1.24M$1.28M$2.85K$3.02KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

PROVECTUS BIOPHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312015-12-312014-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-1575.3%-734.4%-520.2%-346.6%UnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue368.2%207.5%0.5%0.3%UnavailableUnavailable
Current ratio0.08x0.14x0.15x0.23x3.57x22.53x
Revenue YoY growth-45.5%10.7%-43.6%UnavailableUnavailableUnavailable
Net margin-1615.8%-766.9%-556.2%-359.4%UnavailableUnavailable
R&D / revenue564.5%332.3%313.6%241.6%UnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PVCT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.